IFN-gamma

ApprovedSmall molecule

NNational Institute of Allergy and Infectious Diseases (NIAID)

IFN-gamma is one of 29 small molecule programs targeting Chronic Granulomatous Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Granulomatous DiseaseActive, not recruiting

Chronic Granulomatous DiseaseApproved

Active, not recruiting

Competition

Competitive Landscape

42 competitors in Chronic Granulomatous Disease

#DrugCompanyPhaseTrials

Advil

Interferon-Gamma

1 3

Fludara

Sanofi

Phase 2

2 4

Neoral

Novartis

Phase 2

1 5

Busulfex

Akero Therapeutics

Phase 2

5 6

Cytoxan

BBaxter Healthcare Corporation

Phase 2

4 7

Promacta

Actemra

Noxafil

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

1 10

Sporanox

SSebela Pharmaceuticals Development LLC

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Granulomatous Disease1 trial

Biochemical Response to Interferon-Gamma in Subjects With Specific Gene Mutation in Chronic Granulomatous Disease

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 4·NCT01147042·2 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for IFN-gamma. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IFN-gamma compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IFN-gamma. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: NNational Institute of Allergy and Infectious Diseases (NIAID)

IFN-gamma

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Granulomatous Disease1 trial

References

Drug Info

Quick Facts

Related News